Strategic Partners A/S OZYMF OTC · Healthcare · Denmark
$90.00 +0.00% +$0.00
Summary
35 / 100 · Bulios Score
What speaks for it
- Out of every 100 DKK of revenue, 39 DKK is left as net profit.
- It has no debt and holds 70.7K kr in cash.
What to watch
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 209.2 DKK for 1 DKK of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (DKK)
Diluted EPS (DKK)
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Very wellWhere 100 DKK of revenue goes
- Cost of sales 0.0 DKK
- Sales and administration 924 DKK
- Taxes and other -863 DKK
- Net profit 39 DKK
Net profit, industry median (Biotechnology) -9.2 DKK
Out of every 100 DKK of revenue, 39 DKK is left as net profit.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly negative- Buy 0
- Hold 0
- Sell 1
No analyst has published a price target.
0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.